LEISHMANIASIS & Cannabis studies completed
Therapy has long been a challenge in the more severe forms of the disease, and it is made more difficult by the emergence of drug resistance. With the exception of Australia, the Pacific Islands, and Antarctica, the parasites have been identified throughout large portions of the world.
Science and Research
Before and after photo of an infant treated with a topical cannabis medicine
Biologically Active Cannabinoids from High-Potency Cannabis sativa
Nine new cannabinoids were isolated from a high-potency variety of Cannabis sativa. Their structures were identified as (±)-4-acetoxycannabichromene, (±)-3′′-hydroxy-Δ(4′′,5′′)-cannabichromene, (−)-7-hydroxycannabichromane, (−)-7R-cannabicoumarononic acid A, 5-acetyl-4-hydroxycannabigerol , 4-acetoxy-2-geranyl-5-hydroxy-3-n-pentylphenol, 8-hydroxycannabinol, 8-hydroxycannabinolic acid A, and 2-geranyl-5-hydroxy-3-n-pentyl-1,4-benzoquinone through 1D and 2D NMR spectroscopy, GC-MS, and HRESIMS. The known sterol β-sitosterol-3-O-β-d-glucopyranosyl-6′-acetate was isolated for the first time from cannabis.
Compounds 6 and 7 displayed significant antibacterial and antifungal activities, respectively, while 5 displayed strong antileishmanial activity.
As part of our program aimed at the discovery of new cannabinoids and other metabolites with significant biological activity from highpotency cannabis (!9-THC > 10%, w/w), we have reported 25 new metabolites.2-5 In this paper, we report the isolation and identification of nine additional new cannabinoids (1-9), including three cannabichromene derivatives (1-3), (-)-7R-cannabicoumarononic acid A (4), two cannabigerol derivatives (5 and 6), two cannabinol derivatives (7 and 8), and a C21 benzoquinone derivative.
Results and Discussion
Compound 1 was isolated...read full pdf